 MarketWatch (press release) | Chimerix Files Registration Statement for Proposed Initial Public Offering MarketWatch (press release) CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients. Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for ... |
